Healthcare
Live Price
Offline$11.77
-3.52% today
1Y Change
+0.43%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Santen Pharmaceutical Co., Ltd. (SNPHY) is a Healthcare stock with a market cap of $528.52B and listed on OTC. The stock last traded around $11.77 and up 0.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -0.6%, EPS growth of +43.2%, a dividend yield of 2.3%. What stands out right now is revenue -0.6%, EPS +43.2%, free cash flow -12.4% with operating margin 14.3% and ROIC 9.6%. The dividend is present but secondary, with a yield around 2.3%. Valuation is more restrained than many high-expectation growth names at P/E 17.3 and price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNPHY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNPHY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNPHY Max Drawdown
-20.27%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNPHY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$249.6B
-6.3% YoY
FY Net Income
$6.8B
-74.9% YoY
Free Cash Flow
$15.0B
+47.1% YoY
Revenue Growth
-0.6%
EPS Growth
+43.2%
Gross Margin
53.8%
Net Margin
10.6%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 300.0B | 302.0B | 279.0B | 266.3B | 249.6B |
| Gross Profit | 171.0B | 178.7B | 166.1B | 156.6B | 151.4B |
| Operating Income | 46.9B | 38.5B | -3.1B | 35.9B | 37.8B |
| EBITDA | 59.0B | 50.7B | 12.9B | 52.9B | 70.3B |
| Net Income | 36.3B | 26.6B | -14.9B | 27.2B | 6.8B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 93.0B | 94.6B | 57.9B | 83.0B | 62.9B |
| Total Assets | 409.3B | 435.7B | 421.2B | 460.0B | 402.4B |
| Total Liabilities | 124.1B | 130.3B | 127.9B | 123.1B | 95.3B |
| Shareholder Equity | 286.2B | 306.1B | 294.0B | 337.5B | 307.6B |
| Total Debt | 34.2B | 35.2B | 36.2B | 32.9B | 10.1B |
| Net Debt | -93.0B | -59.4B | -21.7B | -50.1B | -52.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
38.8B
-15.7% YoY
Capital Expenditures
23.8B
+33.6% YoY
Free Cash Flow
15.0B
+47.1% YoY
Key ratios
Gross Margin
53.8%
Operating Margin
14.3%
Net Margin
10.6%
ROE
10.9%
Debt / Equity
0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.